Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Oh

Showing results (1071-1080 of 1,146) with videos related to

Pageof 115
Sort By:
Kidney Medicine|August 1, 2020
Time to Initiation of Antihypertensive Therapy After Onset of Elevated Blood Pressure in Patients With Primary Proteinuric Kidney DiseaseDonald J Weaver, Anne Waldo, Gia J Oh, et al.
Cell Death & Disease|June 3, 2016
Proteolytic degradation and potential role of onconeural protein cdr2 in neurodegenerationJ-Y Hwang, J Lee, C-K Oh, et al.
Animal : an International Journal of Animal Bioscience|June 7, 2013
Technical options for the mitigation of direct methane and nitrous oxide emissions from livestock: a reviewP J Gerber, A N Hristov, B Henderson, et al.
Journal of Human Hypertension|May 22, 2009
Impact of hypertension on coronary artery spasm as assessed with intracoronary acetylcholine provocation testK-Y Chen, S-W Rha, Y-J Li, et al.
Glomerular Diseases|February 8, 2023
Association between Psychiatric Disorders and Glomerular DiseaseHailey E Desmond, Clare Lindner, Jonathan P Troost, et al.
Kidney International Reports|January 1, 2020
Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney DiseaseGia J Oh, Anne Waldo, Francisco Paez-Cruz, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 9, 2021
Improving the efficacy of exome sequencing at a quaternary care referral centre: novel mutations, clinical presentations and diagnostic challenges in rare neurogenetic diseasesChristopher Grunseich, Nathan Sarkar, Joyce Lu, et al.
Cell Death & Disease|July 10, 2015
FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosingZ Wang, P Dove, X Wang, et al.
Journal of Dental Research|February 25, 2016
A Randomized Clinical Trial Evaluating rh-FGF-2/β-TCP in Periodontal DefectsD L Cochran, T-J Oh, M P Mills, et al.
European Journal of Immunology|January 3, 2013
Conditional ligands for Asian HLA variants facilitate the definition of CD8+ T-cell responses in acute and chronic viral diseasesCynthia X L Chang, Anthony T Tan, Ming Yan Or, et al.
Pageof 115

Showing results (1071-1080 of 1,146) with videos related to

Sort By:
Pageof 115
Kidney Medicine|August 1, 2020
Time to Initiation of Antihypertensive Therapy After Onset of Elevated Blood Pressure in Patients With Primary Proteinuric Kidney DiseaseDonald J Weaver, Anne Waldo, Gia J Oh, et al.
Cell Death & Disease|June 3, 2016
Proteolytic degradation and potential role of onconeural protein cdr2 in neurodegenerationJ-Y Hwang, J Lee, C-K Oh, et al.
Animal : an International Journal of Animal Bioscience|June 7, 2013
Technical options for the mitigation of direct methane and nitrous oxide emissions from livestock: a reviewP J Gerber, A N Hristov, B Henderson, et al.
Journal of Human Hypertension|May 22, 2009
Impact of hypertension on coronary artery spasm as assessed with intracoronary acetylcholine provocation testK-Y Chen, S-W Rha, Y-J Li, et al.
Glomerular Diseases|February 8, 2023
Association between Psychiatric Disorders and Glomerular DiseaseHailey E Desmond, Clare Lindner, Jonathan P Troost, et al.
Kidney International Reports|January 1, 2020
Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney DiseaseGia J Oh, Anne Waldo, Francisco Paez-Cruz, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 9, 2021
Improving the efficacy of exome sequencing at a quaternary care referral centre: novel mutations, clinical presentations and diagnostic challenges in rare neurogenetic diseasesChristopher Grunseich, Nathan Sarkar, Joyce Lu, et al.
Cell Death & Disease|July 10, 2015
FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosingZ Wang, P Dove, X Wang, et al.
Journal of Dental Research|February 25, 2016
A Randomized Clinical Trial Evaluating rh-FGF-2/β-TCP in Periodontal DefectsD L Cochran, T-J Oh, M P Mills, et al.
European Journal of Immunology|January 3, 2013
Conditional ligands for Asian HLA variants facilitate the definition of CD8+ T-cell responses in acute and chronic viral diseasesCynthia X L Chang, Anthony T Tan, Ming Yan Or, et al.
Pageof 115